ATE393629T1 - Verwendung von cci-779 als antineoplastisches mittel - Google Patents

Verwendung von cci-779 als antineoplastisches mittel

Info

Publication number
ATE393629T1
ATE393629T1 AT01996175T AT01996175T ATE393629T1 AT E393629 T1 ATE393629 T1 AT E393629T1 AT 01996175 T AT01996175 T AT 01996175T AT 01996175 T AT01996175 T AT 01996175T AT E393629 T1 ATE393629 T1 AT E393629T1
Authority
AT
Austria
Prior art keywords
cci
antineoplastic agent
antineoplastic
agent
Prior art date
Application number
AT01996175T
Other languages
English (en)
Inventor
Gary Dukart
James Gibbons
Lisa Speicher
Philip Frost
Carolyn Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE393629T1 publication Critical patent/ATE393629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01996175T 2000-11-15 2001-11-13 Verwendung von cci-779 als antineoplastisches mittel ATE393629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15

Publications (1)

Publication Number Publication Date
ATE393629T1 true ATE393629T1 (de) 2008-05-15

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996175T ATE393629T1 (de) 2000-11-15 2001-11-13 Verwendung von cci-779 als antineoplastisches mittel

Country Status (28)

Country Link
US (3) US20020091137A1 (de)
EP (1) EP1335725B1 (de)
JP (4) JP4472251B2 (de)
KR (1) KR100827942B1 (de)
CN (2) CN102058588A (de)
AR (1) AR031341A1 (de)
AT (1) ATE393629T1 (de)
AU (2) AU2731302A (de)
BR (1) BR0115323A (de)
CA (1) CA2429020C (de)
CY (1) CY1108109T1 (de)
DE (1) DE60133831T2 (de)
DK (1) DK1335725T3 (de)
EA (1) EA007096B1 (de)
ES (1) ES2305134T3 (de)
HK (1) HK1058008A1 (de)
HU (1) HUP0400521A3 (de)
IL (2) IL155871A0 (de)
MX (1) MXPA03004192A (de)
NO (1) NO20032181L (de)
NZ (1) NZ539668A (de)
PL (1) PL207061B1 (de)
PT (1) PT1335725E (de)
SG (1) SG148031A1 (de)
SI (1) SI1335725T1 (de)
TW (1) TWI286074B (de)
WO (1) WO2002040000A2 (de)
ZA (1) ZA200304603B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2762140B1 (de) 2001-02-19 2017-03-22 Novartis AG Behandlung von festen Gehirntumoren mit einem Rapamycin Derivat
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
MXPA03010907A (es) * 2001-06-01 2004-02-17 Wyeth Corp Combinaciones antineoplasicas.
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
EA008379B1 (ru) * 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
JP2005531391A (ja) * 2002-06-27 2005-10-20 微創医療器械（上海）有限公司 薬剤放出ステント
ATE385795T1 (de) * 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
CA2515677A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DK1615640T3 (da) * 2003-04-22 2007-03-12 Wyeth Corp Antineoplastiske sammensætninger
US20060194211A1 (en) * 2003-04-29 2006-08-31 Burczynski Michael E Methods for prognosis and treatment of solid tumors
EP1648454A1 (de) * 2003-07-25 2006-04-26 Wyeth Lyophilisierte formulierung von cci-779
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
RU2006122517A (ru) * 2004-01-08 2008-02-20 Вайет (Us) Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US9006224B2 (en) * 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
EP1962819A1 (de) * 2005-12-20 2008-09-03 Wyeth Steuerung der formstabilität einer cci-779-dosierung durch steuerung der unreinheiten von wirkstoffen
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
EP3142297B1 (de) * 2007-10-03 2019-02-06 Genesis Technical Systems, Corp. Dynamische asymmetrische ringe
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2278966B1 (de) * 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
WO2010017163A1 (en) 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
JP2013527223A (ja) * 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
CA2992629C (en) * 2015-08-24 2020-06-30 Shanxi Yabao Health Products Co., Ltd. Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DK0525960T3 (da) 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
CN1678312A (zh) 2005-10-05
HK1058008A1 (en) 2004-04-30
JP2014088430A (ja) 2014-05-15
MXPA03004192A (es) 2003-09-22
JP4472251B2 (ja) 2010-06-02
NO20032181D0 (no) 2003-05-14
JP2010018620A (ja) 2010-01-28
KR20040029309A (ko) 2004-04-06
SG148031A1 (en) 2008-12-31
AU2731302A (en) 2002-05-27
EA200300566A1 (ru) 2003-10-30
PL362740A1 (en) 2004-11-02
PL207061B1 (pl) 2010-10-29
JP2016094444A (ja) 2016-05-26
US20020091137A1 (en) 2002-07-11
SI1335725T1 (sl) 2008-08-31
JP2004517065A (ja) 2004-06-10
US7189735B2 (en) 2007-03-13
EA007096B1 (ru) 2006-06-30
DE60133831D1 (de) 2008-06-12
US7781446B2 (en) 2010-08-24
WO2002040000A3 (en) 2002-09-06
BR0115323A (pt) 2004-02-17
US20030153593A1 (en) 2003-08-14
IL155871A (en) 2012-03-29
EP1335725A2 (de) 2003-08-20
HUP0400521A3 (en) 2007-05-29
AR031341A1 (es) 2003-09-17
NO20032181L (no) 2003-05-14
CA2429020C (en) 2009-05-26
TWI286074B (en) 2007-09-01
AU2007201324B2 (en) 2010-11-18
US20070142425A1 (en) 2007-06-21
ES2305134T3 (es) 2008-11-01
CA2429020A1 (en) 2002-05-23
PT1335725E (pt) 2008-06-19
WO2002040000A2 (en) 2002-05-23
EP1335725B1 (de) 2008-04-30
ZA200304603B (en) 2004-09-13
KR100827942B1 (ko) 2008-05-13
HUP0400521A2 (hu) 2004-06-28
CY1108109T1 (el) 2014-02-12
NZ539668A (en) 2007-06-29
AU2007201324A1 (en) 2007-04-19
CN102058588A (zh) 2011-05-18
IL155871A0 (en) 2003-12-23
DK1335725T3 (da) 2008-06-30
DE60133831T2 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
ATE393629T1 (de) Verwendung von cci-779 als antineoplastisches mittel
DE60026540D1 (de) Mutilin-derivate und ihre anwendung als antibakterielle mittel
ATE398110T1 (de) 3-aminochinazolin-2,4-dione als antibakterielle mittel
DE60031513D1 (de) Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60106275D1 (de) Dermatologisches mittel
ATE359275T1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
DE60134094D1 (de) C7-taxanester als antitumormittel
DE69920009D1 (de) Isothiazole derivate verwendbar als antikrebsmittel
DE60127997D1 (de) 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
DE60132618D1 (de) 4,6-diphenylpyridinderivate als entzündungshemmende mittel
FR2824267B1 (fr) Composition cosmetique filmogene
ATE333794T1 (de) Verwendung herbizider mittel
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE69806141D1 (de) Indazoleamid-verbindungen als serotoninergene mittel
ATE437860T1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
DE69917451D1 (de) Sulfonylbenzolverbindungen als analgetische und entzündungshemmende mittel
DE60207318D1 (de) Festes kosmetisches Mittel
DE60230470D1 (de) Festes kosmetisches Mittel
DE60120711D1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE69921983D1 (de) Indolderivate als serotonergische mittel
FR2791258B1 (fr) Composition amincissante
DE50111315D1 (de) Endoparasitizide mittel
ATE321761T1 (de) Indolylpiperidinderivate als antihistaminische und antiallergische mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335725

Country of ref document: EP

REN Ceased due to non-payment of the annual fee